Subscribe
Shohta Ueno (L) Edger Brinkman (R)
4 November 2025NewsUnified Patent CourtTom Phillips

Regeneron and CureVac: UPC ‘cannot be ignored’

Growing clout, powerful remedies, and efficiency are making the UPC a game-changer in global litigation, according to LSPN Europe experts. Tom Phillips reports.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
The hidden code in life sciences deals
27 October 2025   As IP plays a more important role in corporate valuations, acquirers are discovering that the biggest risks in life sciences deals aren’t always in the patents—they’re in the code, the algorithms, and the data. A panel at LSPN North America Fall shared why traditional due diligence is no longer enough.
Americas
LSPN panel unpacks critical IP risks in deal-making
23 October 2025   Experts at LSPN North America Fall explore the often-overlooked factors that can make or break transactions, from employee retention strategies to cross-border patent standards.
Americas
Less is more: patent lawyers flip the script after Amgen
22 October 2025   The Supreme Court’s 2023 Amgen ruling turned patent strategy upside down. Now lawyers are rethinking everything they thought they knew about protecting inventions. Marisa Woutersen reports from LSPN North America–Fall.


Editor's picks

Squires: ‘Inherited patent backlog was an absolute dumpster fire’
Americas
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
1 November 2025

Editor's picks

Americas
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
1 November 2025
Americas
Why AI is changing the patent rules faster than anyone can keep up
24 October 2025
Americas
LSPN panel unpacks critical IP risks in deal-making
23 October 2025
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025
Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025
Americas
Top pharma, biotech, and medtech experts gather at LSPN Fall
21 October 2025

More features

US generics company wins patent battle over Merck Serono’s blockbuster MS drug
Novartis counsel warns: ‘Don’t let AI develop without our input’
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
Is Hatch-Waxman litigation for orphan drugs working?
Delegates descend upon Washington, DC for AIPLA Annual Meeting
Novo Nordisk counters rival with $9bn bid for obesity drug developer
‘We're being attacked from all sides’: Thermo Fisher Scientific counsel
China trademarks rankings reveal new entries, hidden gems and big brands